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Abstract
Background: Diabetes is one of the major risk factors for cardiomyopathy and heart failure with reduced ejection
fraction (EF) and highly associated with left ventricular (LV) dysfunction in human. This study aimed 1) to
noninvasively assess cardiac function using echocardiography; 2) to test the hypothesis that like diabetic human,
cardiac function may also be compromised; in spontaneously developed obese, dysmetabolic and diabetic
nonhuman primates (NHPs).
Methods: Cardiovascular functions were measured by noninvasive echocardiography in 28 control, 20
dysmetabolic/pre-diabetic and 41 diabetic cynomolgus monkeys based on fasting blood glucose and other
metabolic status.
Results: The LV end-systolic volume (ESV) was higher while end-diastolic volume (EDV, 12 ± 5.7 mL) and EF
(63 ± 12.8 %) significantly lower in the diabetic compared to control (14 ± 7 mL and 68 ± 9.8 %) group, respectively.
The E/A ratio of LV trans-mitral peak flow rate during early (E) over late (A) diastole was significantly lower in the
diabetic (1.19 ± 0.45) than control (1.44 ± 0.48) group. E-wave deceleration time (E DT) was prolonged in the
diabetic (89 ± 41 ms) compared to control (78 ± 26 ms) group. Left atrial (LA) maximal dimension (LADmax) was
significantly greater in the diabetic (1.3 ± 0.17 cm) than control (1.1 ± 0.16 cm) group. Biochemical tests showed that
total cholesterol and LDL were significant higher in the diabetic (167 ± 63 and 69 ± 37 mg/dL) than both pre-
diabetic (113 ± 37 and 41 ± 23 mg/dL) and control (120 ± 28 and 41 ± 17 mg/dL) groups, respectively. Multivariable
logistic regression analysis demonstrated that LV systolic (reduced EF) and diastolic (abnormal E/A ratio)
dysfunctions are significantly correlated with aging and hyperglycemia. Histopathology examination of the
necropsy heart revealed inflammatory infiltration, cardiomyocyte hypertrophy and fragmentation, indicating the
myocardial ischemia and remodeling which is consistent with the LV dysfunction phenotype.
Conclusions: Using noninvasive echocardiography, the present study demonstrated for the first time that
dysmetabolic and diabetic NHPs are associated with LV systolic (increased ESV, decreased EF, etc.) and diastolic
(decreased EDV and E/A ratio, prolonged E DT, etc.) dysfunctions, accompanied by LA hypertrophic remodeling
(increased LADmax), the phenotypes similarly to those found in diabetic patients. Thus, spontaneously developed
dysmetabolic and diabetic NHPs is a highly translatable model to human diseases not only in the pathogenic
mechanisms but also can be used for testing novel therapies for cardiometabolic disorders.
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Background
Cardiovascular disease remains one of the leading causes
of death in the United States, accounting 52 % type 2
diabetic (T2D) patients who have a higher risk of mor-
tality at comparable levels of coronary artery disease to
those without T2D [1–3]. On the other end, diabetes is
a major risk factor for heart failure with preserved ejec-
tion fraction (EF), and is highly associated with left ven-
tricular (LV) diastolic dysfunction in human [4–6]. A
major limitation to understanding how diabetes exacer-
bates cardiovascular diseases has been the lack of good
translational animal models with both diabetes and car-
diovascular diseases. Although some rodent and rabbit
models have been used to study the pathogenesis of dia-
betes, these models have not been very translatable to
study the mechanisms that link metabolic and cardiovas-
cular disorders [7]. Spontaneously developed obesity-
associated T2D in the nonhuman primates (NHPs) during
adulthood exhibits clinical features of obesity, insulin re-
sistance, dyslipidemia, diabetes, and pancreatic pathology
that are similar to those observed in humans [8–16]. Fur-
thermore, its metabolic progression from insulin resist-
ance through impaired glucose tolerance to overt diabetes,
the pathological changes that occur in the pancreatic islets
as diabetes develops, and the comorbidities that manifest
as a consequence of disease progression are all compar-
able to human diseases.
Echocardiography has been widely used as an essential
diagnostic tool in clinic to noninvasively examine cardiac
structure, ventricular function, non-perfused myocar-
dium, etc. because of convenient, rapid, economical, and
none radiation [4, 17]. Among the echocardiography in-
dices, EF and the E/A ratio of early to late trans-mitral
Doppler inflow velocity (E/A) are commonly used to
evaluate LV function in risk assessment of cardiac death.
These studies showed that EF was a major determinant
of long-term survival in patients with coronary artery
disease [18]. Doppler images of the mitral valve annulus
and trans-mitral propagation velocity have also been
proposed to assess LV compliance and the severity of
diastolic dysfunction [19, 20]. However, there have not
been studies utilizing echocardiography to noninvasively
characterize cardiac functions in NHPs with spontan-
eously developed dysmetabolism and T2D.
Therefore, the aims of this study are to test the hy-
pothesis that like diabetic human, cardiac functions may
also be compromised in spontaneously developed obese,
dysmetabolic and diabetic NHPs, by 1) To establish an
echocardiography method for noninvasive measure-
ments of cardiac functions in NHPs; 2) to determine if
these NHPs also have a compromised LV diastolic dys-
function; and 3) to examine the relationship between the
LV diastolic dysfunction and the accompanying cardio-
vascular risk factors.
Methods
Experiments were carried out in the entire colony of 89 cy-
nomolgus monkeys of either genders then existed onsite,
individually housed under ∼ 21 °C room temperature and a
12 h. light/dark (6 pm–6 am) cycle with continuous access
to water ad libitum and controlled access to food with a
complete nutritionally balanced diet (Shanghai Shilin Bio-
technology, Inc., Shanghai, China) enriched with seasonal
fruits and vegetables. These monkeys had no history of
pharmaceutical treatment in the past 2 months whose
pathophysiological conditions were stable.
The revised guidelines on diagnosis and classification of
T2D in clinic from Diabetes Mellitus Expert Committee is
fasting blood glucose (FBG) ≥126 mg/dL. There is cur-
rently no consensus in research community for the exactly
criteria to define dysmetabolic and diabetic standard for
NHP model. However, the FBG in normal young adult
lean NHP population is typically ~20 mg/dL lower than
that in healthy humans. Therefore, we pre-divided the 3
experimental groups using the below arbiter standard:
control (n = 28, FBG < 85 mg/dL), pre-diabetic/dysmeta-
bolic (n = 20, FBG = 85–125 mg/dL) and diabetic (n = 41,
FBG > 125 mg/dL). The diagnosis of diabetes and dysme-
tabolism is not just based on a single FBG measurement,
it is based on multiple measurements over the progressive
history for at least 3 months, along with other metabolic
parameters such as intravenous glucose tolerance test
(ivGTT), body fat composition measured by dual-energy
X-ray absorptiometry (DEX); HbA1c, insulin and lipids
levels, etc.
Experimental procedures
On the experimental day, monkeys were fasted over-
night and received an intramuscular injection of keta-
mine (Fujian Gutian Pharmaceutical Co. Ltd., Fujian,
China) at an initial dose of 10 mg/kg followed by main-
tenance doses of 5 mg/kg as needed. Body temperature
was maintained at ∼ 37 °C by a thermostatically con-
trolled warm water-circulating pad placed underneath
the animal. Throughout the experimental period, ani-
mals were monitored on the vital signs which may trig-
ger intervention (supportive and/or emergent care) and/
or study termination including: oxygen saturations
<90 %; body temperature <35 °C; heart rate (HR) <100
or >200 beats/min; respiratory rate < 20 or > 60/min,
serious arrhythmia and respiratory artifacts, etc.
Echocardiographic examination
Each monkey underwent a comprehensive transthoracic
scanning with 2-dimensional, M-mode, and pulsed-wave
Doppler echocardiography using an ultrasound system
(ProSound SSD-3500SX, Hitachi Aloka Medical, Ltd.
Tokyo, Japan). Qualified echocardiographic images were
captured and stored for offline analysis with each
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parameter being taken from 3 to 5 consecutive cardiac
cycles to obtain an average value. The LV inner dimen-
sions at end-systolic (LVIDs) and end-diastolic (LVIDd),
and septal dimension (LVSD) along with heart rate (HR)
were measured using M-mode tracing from the paraster-
nal long axis (PLAX) view. From these parameters, frac-
tional shortening (FS), ejection fraction (EF), cardiac
output (CO), end-diastolic (EDV), end-systolic (ESV)
and stroke (SV) volumes were calculated. The LV dia-
stolic filling function was assessed by trans-mitral flow
velocities with pulsed-wave Doppler under the apical
four-chamber view [21]. The peak trans-mitral inflow
velocities at early (E) and late (A) diastole and E-wave
deceleration time (E DT) were measured using pulsed-
wave Doppler with the sample volume at the tip of mi-
tral valve. Left atrial (LA) maximal dimension (LADmax)
was measured by M-mode echocardiography from the
parasternal long axis view. This is a prospective and sin-
gle blind study with echocardiographic operators not
knowing the animal metabolism condition when scan-
ning animals and analyzing the data.
After completion of the echocardiographic scanning,
animals were returned to their home cage and closely
monitored by a trained personnel until completely re-
covery from anesthesia when the animals were in the
upright position and food and water were then provided.
Histopathological examination of the heart tissue
In 1 male and 1 female diabetic monkeys with LV dia-
stolic dysfunction and LA remodeling who died naturally
due to unknown reasons (aging, diabetes and its compli-
cations, etc.), necropsy was performed and the hearts
were collected and placed in 4 % paraformaldehyde, and
then imbedded with paraffin. Tissues were cut into 5 μm
sections and stained with hematoxylin and eosin (H&E).
Histopathological changes were examined via light mi-
croscopy by a histopathologist.
The experimental protocol and procedures were ap-
proved by the Institutional Animal Care and Use Com-
mittee (IACUC) of Crown Bioscience, Inc. and in
accordance with the guidelines of Association for As-
sessment and Accreditation of Laboratory Animal Care
(AAALAC).
Statistical analysis
All the data were expressed as mean ± standard error
(SE). Statistical analysis was conducted using SPSS 17.0
software (SPSS for Windows, version 21.0; IBM-SPSS,
Chicago, Illinois, USA). Student t-test was used to com-
pare the mean values between 2 experimental groups.
One-way analysis of variance (ANOVA) was used for
comparison of the mean values among 3 experimental
groups.
Univariate logistic regression analysis was conducted
to examine the relationships between the prevalence of
LV dysfunction with other parameters such as age, fast-
ing blood glucose, HbA1c, insulin treatment, gender, etc.
To simplify the analysis, the below arbiter cut-off values
were used. LV systolic dysfunction defined as EF <55 %
and diastolic dysfunction as E/A ratio <1 or >2 were
used to associate with aging (>10 years old), hypergly-
cemia (FBG > 85 mg/mL), HbA1c (>7 %), insulin treat-
ment, gender, etc. Currently, there is no consensus in
the research community for the exact definition of the
above abnormality for NHP model. First, a multiple lo-
gistic regression analysis using a step-wise backward
method was conducted with the prevalence of LV dys-
function as dependent and all other factors as independ-
ent variables, which were significantly associated with
myopia prevalence in the univariate analysis. Multivari-
able logistic regression analysis with odds ratios and
95 % confidence intervals (CI) were then used to exam-
ine the associations between animals with certain risk
factors and those without. Certain risk factors identified
by univariate analyses were subjected to multivariable
logistic regression analysis as independent variables. All
P-values were 2-sided and considered statistically sig-
nificant when < 0.05.
Results
Basic characteristics (Table 1)
The diabetic group was older than the other 2 groups.
The fasting blood glucose (FBG) was significantly higher
in the pre-diabetic, and the highest in diabetic compared
to control group. The blood lipid concentrations, includ-
ing TG, CHO and LDL were significantly higher and
HDL lower, thus, LDL/HDL ratio higher in the diabetic
than control or pre-diabetic groups. There were no sig-
nificant differences in age, body weight, HbA1c and
blood lipid levels between the control and pre-diabetic
NHPs.
Table 1 Animals Characteristics
Control Pre-diabetes Diabetes
Number, n (%) 28 (31.5 %) 20 (22.5 %) 41 (46.1 %)
Age (year) 11 ± 1 12 ± 2 18 ± 1**##
Weight (kg) 9 ± 1 9 ± 1 8 ± 1*
FBG (mg/dL) 66 ± 4 99 ± 3** 227 ± 20**##
HbA1c (%) 4.7 ± 0.6 5.2 ± 0.6 9.1 ± 0.8**##
CHO (mg/dL) 120 ± 7 113 ± 9 167 ± 15**##
TG (mg/dL) 63 ± 7 82 ± 8 217 ± 36**##
HDL (mg/dL) 54 ± 4 48 ± 4 48 ± 5**
LDL (mg/dL) 41 ± 4 41 ± 6 69 ± 9**##
CHO/HDL 2.2 ± 0.5 2.3 ± 0.1 3.5 ± 1.8*#
*& **P < 0.05 & 0.01 vs. Control, # & ##P < 0.05 & 0.01vs. Pre-diabetes
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Cardiac functions measured by noninvasive
echocardiography
There were no significant differences in LV dimensions
(LVSd, LVIDs, LVIDd and LVPWd) and mitral valve pa-
rameters (MVAmax and VMVmax) among 3 experimen-
tal groups although the trans-mitral valve pressure
gradient (MV ΔP) significantly elevated in the diabetic
NHPs (Table 2).
Left ventricular systolic dysfunction (Fig. 1)
The LV ejection fraction (EF), fraction shortening
(FS), stroke volume (SV) and cardiac output (CO)
were significantly lower in the diabetic compared to
both control and pre-diabetic groups. Both the SV
and CO, but not EF and FS were significantly lower
in the pre-diabetic than control group. The LV end-
systolic volume (ESV) and heart rate (HR) were not
significantly different among 3 groups. The original M
mode images obtained from the representative ani-
mals showed expended LV inter dimension at both
end-diastolic (LVIDd) and end-systolic (LVIDs) phases
in the diabetic compared to control one.
Left ventricular diastolic dysfunction (Fig. 2)
The peak mitral flow rate during early (E-wave) but
not late (A-wave) diastole was significantly lower in both
the pre-diabetic and diabetic compared to control group.
As a result, E/A ratio was significantly lower only in the
diabetic compared with control group. The original
pulsed-wave echocardiographic images obtained from
the representative animals showed that the E/A ratio
was reversed in the diabetic compared to control animal.
The LV end-diastolic volume (EDV) was significantly
lower and E-wave deceleration time (E DT) prolonged
only in the diabetic, but not pre-diabetic compared to
control group. The maximum LA dimension (LADmax)
was significantly higher in the pre-diabetic and the high-
est in diabetic compared to control group, indicating LA
remodeling resulted from LV dysfunction.
Association of left ventricular dysfunctions with aging,
hyperglycemia and insulin treatment (Fig. 3)
The incidences of low EF and abnormal E/A ratio in
old and hyperglycemic NHPs were significantly higher
than those in young (Left) and normal glycemic (Middle)
ones. Consistently, in 32 NHPs with HbA1c >7 %, there
were 30 (94 %) with low EF, while in 57 NHPs with
HbA1c ≤7 %, there were only 18 (32 %) with low EF, the
difference in the incidence of LV dysfunctions between
the normal and high HbA1c group being statistically sig-
nificant with OR = 32.5, CI 95 % 29.0–36.0, P < 0.05. The
incidence of abnormal E/A ratio, but not low EF was sig-
nificantly higher in overly diabetic NHPs with insulin
treatment for more than 6 months than those without
insulin treatment (Right). In contrast, the gender seemed
not an independent predictor of LV dysfunctions (data
not shown).
Histopathology of cardiomyopathy (Fig. 4)
In 2 representative diabetic monkeys with significant
LV diastolic dysfunction and LA remodeling revealed
by echocardiography, histopathological examination of
the necropsy heart was performed postmortem. In a
23 year old female animal with sever hyperglycemia
and significantly reduced E/A ratio, there were focal
myocardial inflammation with inflammatory cell infil-
trated around the small vascular and myocardial
edema (A), as well as some signs of myocardial ische-
mia such as of myocardial muscle fiber fragmentation
and increased eosinophils (B). In another 21 year old
male animal with diabetes and reduced E/A ratio, the
H&E staining showed signs of myocardial ischemia
and cardiac muscle atrophy with accumulation of
brown granules at the nuclear poles of the cardiac
muscle fiber cytoplasm (C).
Discussion
Using noninvasive echocardiography, the present study
detected left ventricular dysfunction for the first time
Table 2 Echocardiography parameters
Control (n = 28) Pre-Diabetes (n = 20) Diabetes (n = 41)
LV dimensions
LVSd (mm) 3.7 ± 0.2 3.9 ± 0.1 3.4 ± 0.2
LVIDs (mm) 11.9 ± 0.1 11.6 ± 0.2 11.9 ± 0.1
LVIDd (mm) 21.4 ± 0.4 19.9 ± 0.4 19.3 ± 0.4
LVPWd (mm) 4.8 ± 0.1 5.0 ± 0.1 4.6 ± 0.4
Mitral Valve parameters
MVAmax (cm2) 1.1 ± 0.1 1.1 ± 0.1 0.9 ± 0.1
VMVmax(cm/sec) 83 ± 4 79 ± 4 84 ± 4
MV ΔP (mmHg) 2.6 ± 0.3 2.6 ± 0.3 3.0 ± 0.4*##
*P < 0.05, vs. Control; ## P < 0.01, vs. Pre-diabetes
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in spontaneously developed obese, dysmetabolic and
diabetic NHPs and its interaction between the LV dys-
functions and metabolic disorders, which is consistent
with human disease.
The optimal performance of LV depends on its con-
verting ability between systolic ejection and diastolic fill-
ing. Strong systolic contractility causes quick rise of LV
pressure that enables blood to be effectively ejected into
the aorta under high pressure gradient between the LV
and aorta, while good diastolic compliance enables blood
quickly and effectively to fill the LV from LA under low
pressure condition that prompts the next contraction
phase. Either systolic or diastolic dysfunction would
compromise cardiac function to effectively pump blood
for supplying the body needs.
Systolic dysfunction
Rubler et al. first described the existence of ‘diabetic
cardiomyopathy’ in 1972 based on some adult diabetic
patients with chronic heart failure that could not be ex-
plained by coronary artery disease, hypertension, valvu-
lar heart disease, or alcoholism [22]. In prospective
studies, approximately half of the heart failure patients
have abnormal resting EF [23, 24], which is an important
prognostic variable for survival prediction [8]. This hy-
pothesis is supported by the data from Mayo clinic dem-
onstrating a significantly worse survival in asymptomatic
diabetic patients with EF <50 % [25]. Similar to the large
epidemiological investigation in human [26-28], the
present study demonstrated a significantly lower EF, along
with FS, CO and SV in the diabetic compared with non-
Fig. 1 Left ventricular systolic dysfunction in control, pre-diabetic/dysmetabolic and diabetic NHPs. Group mean values +/− SE of LV ejection fraction
(EF), stroke volume (SV), end-systolic volume (ESV), fractional shortening (FS), cardiac output (CO) and heart rate (HR). *P < 0.05 vs. control, # P < 0.05 vs.
pre-diabetes. The original M mode echocardiography images in parasternal long axis for measurement of left ventricular inter dimensions at end-
diastole (LVIDd) and end-systole (LVIDs) were obtained from a control and a diabetic monkey
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diabetic NHPs, indicating compromised LV contractility
with global systolic dysfunction in this colony. The refer-
ence standard from American Society of Echocardiog-
raphy sets resting EF <55 % as abnormal LV systolic
function with 45–55 % as mild, 30–45 % as moderate, and
<30 % as severe reduction [29]. According to this standard,
the present data demonstrated that both aging and hyper-
glycemia strongly associated with the incidence of LV sys-
tolic dysfunction (low EF). Insulin treatment represents the
advanced stage of diabetes progress, thus should also be as-
sociated with LV systolic dysfunction, however, it did not
reach statistical significance in the present study, probably
due to the weak statistical power resulted from small num-
ber of insulin treated animals included in this study.
Elevation of LV ESV also indicates reduced systolic
function. Multivariate analysis identified ESV as an
independent predictor of cardiac death after adjustment
for perfusion and EF data. Tali et al. reported that if ESV
= 70 mL is defined as a threshold, patients with severe
perfusion abnormalities but ESV ≤ 70 mL had very low
cardiac death rates (0.4 %/year), whereas patients only
with mild/moderate perfusion defects but ESV > 70 mL
had high cardiac death rates (8.2 %/year) [8]. In the
present study there is no significant different in ESV
among the 3 groups, which is probably due to LV sys-
tolic dysfunction in this colony of diabetic NHPs may
not be severe enough to cause ESV reduction.
Diastolic dysfunction
Diastole is the portion of the cardiac cycle that begins
with aortic closure and ends with mitral closure. In-
creased LV stiffness or decreased LV compliance would
Fig. 2 Left ventricular diastolic dysfunction in control, pre-diabetic/dysmetabolic and diabetic NHPs. Group mean values +/− SE of trans-mitral peak flow
rate during the early (E-wave) and late (A-wave) diastole, E/A ratio, LV end-diastolic volume (EDV), left atrial maximal dimension (LADmax), LV E-wave
deceleration time (E DT). *& **P< 0.05 & 0.01 vs. control, ## P< 0.01 vs. pre-diabetes. The original pulsed-wave Doppler echocardiography images showed
mitral peak inflow velocities at early (E) and late (A) diastole and E wave deceleration time (E DT) measured with the sample volume at the tip of mitral
valve from a control and a diabetic monkey
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cause abnormality in LV relaxation, alter the onset, rate,
and extent of LV pressure decline, thus, building resist-
ance to LV filling, which are important pathophysiologic
mechanisms in LV diastolic dysfunction [30]. These
changes create an abnormal LV pressure-volume relation
so that higher filling pressure is required to maintain
normal EDV and cardiac output. Mitral E-wave velocity
primarily reflects early diastolic LA-LV pressure gradient
that is also influenced by preload and LV relaxation
function [31]. LV elastic recoil and diastolic pressure dir-
ectly impact mitral E-wave velocity and time interval
(e.g. E DT). Indeed, the present data demonstrated that
dysmetabolic and diabetic NHPs are associated with de-
creased EDV and peak E-wave velocity as well as pro-
longed E DT. Mitral A-wave reflects late diastolic filling
velocity as a result of LA contraction, which is not sig-
nificantly different among the 3 groups. Thus, E/A ratio
was significantly lower in diabetic NHPs. These results
demonstrated LV diastolic dysfunction in dysmetabolic
and diabetic NHPs, which is consistent with that in dia-
betic patients [20, 32, 33].
Left atrial remodeling
LA remodeling is a continuous process under chronic
diastolic burden or as long as cardiovascular risk factors
or diseases still persist. Thus, LA enlargement becomes
a reliable indicator of advanced diastolic dysfunction, re-
gardless of LV systolic function, underlying cardiovascu-
lar disease or LV hypertrophic remodeling [34]. Patients
with LV systolic dysfunction and heart failure showed
that LA systolic and diastolic dimensions were inde-
pendent predictors of exercise capacity and cardiovascu-
lar events (cardiac death or hospitalization for heart
failure) [35]. In deed in the present study, diabetic NHPs
presented with greater LADmax than controls, a strong
evidence of LA remodeling, which could be a morpho-
logical adaptation to LV dysfunction or direct effects of
hyperglycemia.
There is evidence supporting the existence of diabetes-
induced direct structural and functional alterations in
the myocardium [36]. Glycosylation products accumu-
late and cross-link with collagen in blood vessel walls
and interstitial tissues contributing to micro-angiopathy.
Cross-linking of proteins by glycosylation products also
facilitates inflammatory cell invasion and LDL deposition
in the vascular walls leading to atherosclerosis and focal
inflammation, which in turn would cause myocardial is-
chemia. In diabetes, the equilibrium between energy
production and utilization is disrupted in the myocar-
dium [37]. Hyperglycemia results in increased intracellu-
lar glucose concentrations in myocardial cell and
glucose metabolism products, which in turn increases
the osmotic pressure in myocardium that stimulates the
influx of water leading to cellular edema, thus, cardio-
myocyte rupture. Oxidative imbalance-induced increase
in oxidative stress, cardiomyocyte apoptosis and hyper-
trophy, as well as myocardial edema and fibrosis, have
been suggested to be the key pathological features of de-
velopment and progression of diabetic cardiac complica-
tions [38]. In the present study, the histopathological
Fig. 3 Association of left ventricular systolic (EF < 55 %) and diastolic (E/A < 1 or ≥ 2) dysfunction with aging (≥ 10 years old), hyperglycemia
(FBG≥ 85 mg/mL) and insulin treatment for more than 6 months
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examination with the evidences of inflammatory infiltra-
tion in the myocardium as well as cardiomyocytes hyper-
trophy, edema and fragmentation is consistent with the
echocardiographic observations on LV remodeling and
LA diastolic dysfunction.
Diabetes has such an important influence on the de-
velopment of congestive heart failure that it has been in-
corporated as a risk factor in the guidelines by American
College of Cardiology/American Heart Association [39].
Hyperglycemia causes arterial basement membrane gly-
cosylation that is a strong risk for atherosclerosis and as-
sociates with the development of diabetes-induced LV
diastolic dysfunction [40-43]. Furthermore, high HbA1c
was also an independent risk factor for LV dysfunction,
e.g., each 1 % increase in HbA1c value has been associated
with an 8 % increase in the risk of heart failure [42, 43].
Diabetes is often accompanied by dyslipidemia. Indeed the
present data showed that the blood concentrations of tri-
glyceride, total and LDL cholesterols were elevated and
HDL reduced, thus, the ratio of LDL/HDL increased. It
has been well-established that dyslipidemia closely associ-
ated with abnormalities in LV functions, which is also a
high risk factor for atherosclerosis. Therefore, the accom-
panied dyslipidemia in the current NHP model of dysme-
tabolism and diabetes also contribute at least partially to
the pathogenesis of cardiac dysfunction.
Conclusions
Using noninvasive echocardiography, the present study
demonstrated for the first time that obese, dysmetabolic
and diabetic NHPs are associated with LV systolic (in-
creased ESV, decreased EF, etc.) and diastolic (decreased
EDV and E/A ratio, prolonged E DT, etc.) dysfunctions
similarly to that in diabetic patients. In addition, similar
pathogenic characteristics and accompanying risk factors
are observed in both humans and NHPs. This makes the
current NHP model of spontaneously developed obese, dys-
metabolism and diabetes a unique translational tool not
only for studying early development and environmental fac-
tors that affect the pathogenesis of obesity, dysmetabolism
and diabetes, but also can be used for testing novel
pharmacological interventions for cardiometabolic
disorders.
Abbreviations
A- or E-wave (cm/sec): Trans-mitral peak flow rate during the late or early diastolel;
CHO (mg/dL): Total cholesterol; CO (L/min): Cardiac output; E DT (ms): E-wave
deceleration time; EDV or ESV (mL): End-diastolic or end-systolic volume; EF
(%): Ejection fraction; FBG (mg/mL): Fasting blood glucose; FS (%): Fractional
shortening; HbA1c (%): Hemoglobin A1c; HDL or LDL (mg/dL): High or low
density lipoprotein; LA or LV: Left atrial or ventricle; LADmax (cm): Left atrial
maximal dimension; LVIDd or LVIDs (mm): Left ventricular inner dimension at
end-diastole or end-systole; LVPWD (mm): Left ventricular posterior wall
dimension; LVSD (mm): Left ventricular septal dimension; MV ΔP (mmHg):
Trans-mitral valve pressure gradient; MVAmax (cm2): Maximal mitral valve area;
MVVmax (cm/sec): Maximal trans-mitral valve velocity; NHP: Nonhuman primate;




Fig. 4 H&E staining from 2 representative diabetic monkeys with left
ventricular diastolic dysfunction (Amplification: 20X for the original
and 40X for corner image). a & b: A 23 year old female monkey with
hyperglycemia (FBG: 429 mg/mL, HbA1c: 10.4 %), significantly
reduced E/A (0.64) as well as increased E DT (144 ms) and LADmax
(1.76 cm). a Focal myocardial inflammation: Inflammatory cell
infiltration around the small vascular and light myocardial cell
edema (indicated by ➡). b Broken myocardial muscle fibers with
increased eosinophils (indicated by ➡). c A 21 years old male
monkey with hyperglycemia (FBG: 247 mg/mL, HbA1c: 11.2 %),
significantly reduced E/A (1.01) as well as increased E DT (159 ms)
and LADmax (1.31 cm). Sings of myocardial ischemia and cardiac
muscle atrophy: Accumulation of brown granules at the nuclear
poles of the cardiac muscle fiber cytoplasm (indicated by ➡)
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